Introduction {#s1}
============

Diabetes and cardiovascular disease (collectively referred to as vascular disease) are leading causes of mortality and morbidity throughout the world [@pone.0066454-World1], [@pone.0066454-Kanavos1]. Rates of obesity and diabetes are rising at an alarming pace across Europe [@pone.0066454-Anand1]. Managing vascular disease over the coming decades will require an integrated approach to addressing established modifiable risk-factors. Population level screening should be a central element of any management strategy, because the early stages of vascular disease are often asymptomatic, and many individuals remain undiagnosed until debilitating and costly complications occur [@pone.0066454-Spijkerman1], [@pone.0066454-Schwarz1], [@pone.0066454-Lewington1], [@pone.0066454-Lewington2].

The NHS Health Check program was developed in the United Kingdom (UK) to address this problem [@pone.0066454-Davies1], [@pone.0066454-NHS1]. The Health Checks program integrates the prevention, early detection, and treatment of type 2 diabetes, hypertension, dyslipidemia, and smoking. Further, previous modeling studies have indicated that health checks and screening for diabetes are likely to be cost effective [@pone.0066454-Department1], [@pone.0066454-Kahn1], [@pone.0066454-Gillies1].

In this study, we used the Archimedes Model to estimate the cost effectiveness of offering a range of health check strategies to individuals in six European populations, compared to current levels of care in each country. Our study provides a broader understanding than prior studies by forecasting the impact of offering health checks that address multiple aspects of vascular disease, recurring every five years, in six European settings.

Methods {#s2}
=======

We simulated a clinical trial comparing seven health check strategies to current levels of care in Denmark, France, Germany, Italy, Poland, and the UK. For each country, we forecasted the impact of each strategy on the incidence of major adverse cardiovascular events, and diabetes related microvascular complications, as well as medical costs, and quality adjusted life years (QALYs).

Mathematical Model {#s2a}
------------------

Our estimates were made with the Archimedes Model, a person-specific simulation model designed to capture what happens in real health care systems at a clinically meaningful level of detail. The Model forecasts health outcomes and health care utilization associated with diabetes and its complications, coronary artery disease, congestive heart failure, stroke, hypertension, obesity, metabolic syndrome, and cancers of the breast, lung, and colon. Including all relevant conditions and the health care system in a single integrated model captures interactions between diseases and comorbidities in a physiologically realistic way. Details of the Model pertinent to diabetes and its complications have been described elsewhere [@pone.0066454-Eddy1], [@pone.0066454-Eddy2], [@pone.0066454-Archimedes1], and a description of the model structure and data sources used in the modeling is provided as [File S2](#pone.0066454.s002){ref-type="supplementary-material"}.

In brief, the Model uses person-specific data to generate simulated individuals, each having a unique physiology that evolves continuously over time, and which can begin to function abnormally in the case of disease, potentially causing symptoms, changes in biomarkers, and ultimately health outcomes. The Model includes detailed representations of the health care system, with acute and ambulatory care settings, physicians, medical tests, and so on. The simulated health care system is calibrated to match patterns of health care delivery observed in the target setting ([File S3](#pone.0066454.s003){ref-type="supplementary-material"}). The data sources used to model the benefits of lifestyle, anti-platelet, anti-diabetic, anti-hypertensive, and lipid lowering therapies are provided as [File S2](#pone.0066454.s002){ref-type="supplementary-material"}.

The accuracy of the Archimedes Model has been validated through simulations of a large number of epidemiological, clinical, and health service research studies [@pone.0066454-Eddy3]. More than 50 clinical trials in both US and European settings have been used to validate the Model, and a full validation report is provided as [File S4](#pone.0066454.s004){ref-type="supplementary-material"} and on the Archimedes website [@pone.0066454-Archimedes1]. Further, two validations have been performed prospectively [@pone.0066454-Mount1], including the CARDS study [@pone.0066454-Colhoun1] which enrolled a UK population.

Procedure {#s2b}
---------

We simulated the effects of offering health checks to six European cohorts. For each country, we used a three step process to generate a study cohort of virtual individuals aged 40 to 75, without a previous diagnosis of diabetes, myocardial infarction, stroke, or serious chronic kidney disease (CKD) (with estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2). First, we generated a population cross-section of all adults aged 20 to 85, matching the demographics and distributions of risk factors observed in real-world data. This population was generated via biased sampling of simulated individuals, based on real subjects observed in NHANES 1999--2008 [@pone.0066454-Centers1]. This approach to constructing simulated European cohorts using biased sampling of virtual individuals based on US data has been demonstrated to be predictive in the trial validations cited above. The specific real-world data used to create the simulated populations varied by country, but included biomarker and risk factor distributions, as well as the prevalence and incidence of diseases addressed by the health check. A complete listing of the data used is provided in [File S1](#pone.0066454.s001){ref-type="supplementary-material"}. Second, the performance of the simulated health care system was calibrated to match levels of care currently being delivered in the country, in terms of the prevalence and incidence of diagnoses, medication use (e.g., anti-hypertensive, statin, and anti-diabetic treatments), and the disease burden in the country (including type 2 diabetes, nephropathy, retinopathy, neuropathy, myocardial infarction, stroke, cardiovascular death, and mortality). These first two steps we repeated iteratively until we obtained a simulated population and health care system reflective of the target country. Lastly, the study cohort -- individuals eligible for the health check -- was extracted from the population cross-section using the eligibility criteria stated above. This three-step process was repeated for each country, yielding six study cohorts.

For each country, we simulated a multi-armed clinical trial comparing the health check strategies to a control scenario in which no health checks were offered (see [Table 1](#pone-0066454-t001){ref-type="table"} for a list of the strategies). The control scenario was reflective of current care in each country. The health check frequency was every five years, but ceasing at age 70 or upon diagnosis of diabetes, myocardial infarction, stroke, or chronic kidney disease. In the base-case health check, all individuals received assessments for diabetes, hypertension, lipids, and smoking. Consistent with current guidelines, diabetes risk was assessed with an HbA1c test [@pone.0066454-International1], [@pone.0066454-AmericanDiabetes1]. Individuals confirmed by two tests to have HbA1c of 6.5% or higher were diagnosed with type 2 diabetes, and referred to a diabetes management protocol [@pone.0066454-Nathan1]. Individuals with HbA1c above 6.0% but less than 6.5% were offered intensive lifestyle advice. Hypertensive individuals (blood pressure above 140/90 mmHg) were referred to a management protocol based on the JNC7 guideline [@pone.0066454-Joint1]. Individuals classified as high risk according to the ATP-III guideline [@pone.0066454-ExpertPanelon1], [@pone.0066454-Grundy1] and with LDL cholesterol greater than 5.59mmol/L were referred for statin therapy. All smokers were offered a smoking cessation intervention.

10.1371/journal.pone.0066454.t001

###### Simulated health check strategies and control.
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                                                                                              Eligibility criteria for risk assessments, for individuals offered a health check         
  ------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------- ------ ------
  **Control -- No health checks offered**                                                                                           None                                          None   None
  **Health check -- base-case**                                                                                                      All                                          All    All
  **Health check without lifestyle interventions**                                                                                   All                                          All    None
  **Health check with gated HbA1c test**                                                                                   BMI ≥ 30 or BP ≥ 140/90                                All    All
  **Pre-screening scenarios targeting patients meeting the following additional criteria**                                                                                              
  ** Age 50 years or greater**                                                                                                       All                                          All    All
  ** BMI 30 kg/m^2^ or greater**                                                                                                     All                                          All    All
  ** Above median of diabetes and CVD risk**                                                                                         All                                          All    All
  ** Top quartile of diabetes and CVD risk**                                                                                         All                                          All    All

In all cases, individuals had to be aged 40--75 and not have a previous diagnosis of diabetes, myocardial infarction, stroke, or serious chronic kidney disease to be eligible for a health check. In the pre-screening strategies, individuals also had to meet the additional criteria listed in the table. Eligible individuals received the health check at a 5 year interval in all strategies considered.

Eligible individuals were given an HbA1c test.

Diet and exercise for individuals with 6.0% ≤ HbA1c \<6.0%, and smoking cessation interventions for smokers.

We examined providing a health check that only included an HbA1c test for obese (BMI ≥30 kg/m^2^) and/or hypertensive individuals, reflective of the strategy used by the NHS Health Checks program. We also examined the effects of offering a health check without lifestyle interventions (omitting intensive lifestyle advice and smoking cessation) to the entire study cohort to gauge the impact of the interventions on the results, since the benefits of lifestyle interventions are more difficult to quantify than pharmacological interventions.

In consideration of total budget impact, four strategies examined various ways to pre-screen the study cohort, and restrict eligibility for the health check to individuals with elevated risk of vascular disease (also shown in [Table 1](#pone-0066454-t001){ref-type="table"}).

To explore how pre-screening the population with a non-invasive risk test might make the health check more efficient, we created a "virtual", generic risk test based on simulated data. This generic risk test had the independent risk factors of age, gender, BMI, waist circumference, smoking, family history of diabetes, family history of coronary heart disease, and anti-hypertensive usage. The generic risk test had a logistic functional form, and was based on a logistic regression performed on the presence of undiagnosed diabetes at baseline or the ten-year occurrence of myocardial infarction, stroke, or CV death, in half of the simulated Danish population cross-section of adults aged 20 to 85. Two thresholds were considered for the risk test: individuals in the top quartile of risk, and individuals above median risk, as predicted by the logistic score. The performance of the generic risk test in detecting undiagnosed diabetes at baseline or the ten-year occurrence of myocardial infarction, stroke, or CV death was then tested on the remaining half of the simulated Danish population cross-section, as well as the population cross-sections of the remaining five countries, and the results are shown in [Table 2](#pone-0066454-t002){ref-type="table"}. Further details on the creation and validation of the generic risk test are provided in [File S1](#pone.0066454.s001){ref-type="supplementary-material"}. Our use of this virtual, generic diabetes and CVD risk test is intended to show what might be achieved with risk test based pre-screening strategies. A real-world program would use a real-world risk test, with similar sensitivity and specificity, evaluated on data provided by the individual (like FINDRISC [@pone.0066454-Lindstrom1]), or from data in general practice databases (like the Cambridge diabetes risk score [@pone.0066454-Rahman1]).

10.1371/journal.pone.0066454.t002

###### Performance of the generic risk score in detecting undiagnosed type 2 diabetes at baseline or the occurrence of CVD at ten years, for individuals with estimated risk in the top quartile (25%) and top half (50%) of the population ranked by risk score.

![](pone.0066454.t002){#pone-0066454-t002-2}

                               Denmark   France   Germany   Italy   Poland    UK                                            
  --------------------------- --------- -------- --------- ------- -------- ------- ------- ------- ------- ------- ------- -------
  Positive Predictive Value     0·206    0·136     0·189    0·131   0·272    0·189   0·194   0·141   0·199   0·138   0·260   0·177
  Negative Predictive Value     0·965    0·981     0·963    0·981   0·946    0·971   0·952   0·971   0·961   0·980   0·952   0·976
  Sensitivity                   0·664    0·879     0·628    0·871   0·625    0·868   0·573   0·831   0·631   0·875   0·646   0·880
  Specificity                   0·785    0·532     0·781    0·530   0·796    0·545   0·780   0·531   0·783   0·532   0·794   0·543
  Likelihood Ratio              3·084    1·877     2·866    1·854   3·061    1·906   2·606   1·772   2·902   1·870   3·142   1·923

Based on expert opinion, we assumed that 50% of patients would adhere to treatments triggered by the health check. We conservatively assumed that patients who had previously not adhered to prescribed treatments would remain non-adherent to care prescribed by the health check. For intensive lifestyle advice, we assumed that 50% of patients referred would maintain a 3% weight loss for life, based on trials of commercial programs [@pone.0066454-Tsai1], [@pone.0066454-Jebb1]. We assumed that 10.5% of smokers who received smoking cessation interventions would successfully quit, and that the cost would be £224 per successful quitter, based on studies from the UK [@pone.0066454-Lader1], [@pone.0066454-Ferguson1], rescaled according to the relative cost of care in each country. Finally, we did not attribute a cost to the evaluation of the generic risk test because the cost is currently unknown. The cost of the test will vary depending on the implementation chosen (e.g. the generic risk test might be performed through mailed forms, web-based forms, or general practice database analyses).

Study outcomes and statistical analyses {#s2c}
---------------------------------------

Simulated individuals were followed for 30 years or until death. We tracked the effect of health checks on the incidence of diagnoses of type 2 diabetes, major adverse cardiovascular events (MACE, first occurrence of myocardial infarction, stroke, or cardiovascular death), and a composite of serious microvascular complications (first occurrence of diabetes related blindness, CKD, end stage renal disease, renal death, foot ulcer, or foot amputation). We computed the number needed to screen (NNS) in order to prevent one additional event using the Kaplan­Meier survival curves [@pone.0066454-Altman1].

Direct medical costs were considered from a governmental payer perspective, adjusted to 2011 amounts, and reported in euros. Country-specific data on medical test, treatment, and health care delivery costs were used to estimate the direct medical costs associated with vascular disease in each country. In instances where specific data were unavailable, we used rescaled Medicare costs. We calculated QALYs based on the time individuals spent with different disorders using published disutilities [@pone.0066454-Sullivan1], [@pone.0066454-Coffey1]. [Table 3](#pone-0066454-t003){ref-type="table"} shows the disutilities, and [Table 4](#pone-0066454-t004){ref-type="table"} shows the costs of visits, tests, and treatments used. Costs and QALYs were discounted at an annual rate of 3%. Variations and uncertainty about costs, disutilities, and discount rates were studied through sensitivity analyses. Outcomes were considered significant for p\<0·05.

10.1371/journal.pone.0066454.t003

###### Base-case model input assumptions for quality of life disutilities.
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  Quality of life disutilities             
  ------------------------------ --------- --------------
  Angina                          −0·0412   Sullivan^29^
  Myocardial infarction           −0·0409   Sullivan^29^
  Stroke                          −0·0460   Sullivan^29^
  End stage renal disease         −0.0780    Coffey^30^
  Blind in one eye                −0.0430    Coffey^30^
  Blind in two eyes               −0.1700    Coffey^30^
  Foot ulcer                      −0·0990    Coffey^30^
  Foot amputation                 −0.1050    Coffey^30^
  Multiple chronic conditions              
  2                               −0·0942   Sullivan^29^
  3                               −0·0876   Sullivan^29^
  4                               −0·0711   Sullivan^29^
  5                               −0·0547   Sullivan^29^
  6                               −0·0419   Sullivan^29^
  7                               −0·0350   Sullivan^29^
  8                               −0·0344   Sullivan^29^
  9                               0·0026    Sullivan^29^
  10                              0·0097    Sullivan^29^

10.1371/journal.pone.0066454.t004

###### Base-case model input assumptions for costs, in euros.
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  Costs (€)                                                Denmark   France   Germany   Italy    Poland     UK
  ------------------------------------------------------- --------- -------- --------- -------- -------- --------
  Outpatient visit[\*](#nt104){ref-type="table-fn"}         99.71    23.00     34.77    22.85     6.25    35.48
  Blood pressure measurement                                  0        0         0        0        0        0
  HbA1c test                                                14.52    14.40     21.30    12.66     4.97    11.65
  Lipid panel                                               15.74    14.60     21.60    25.55     5.04    11.81
  Treatment costs (per day, unless indicated otherwise)                                                  
  Intensive lifestyle advice                                0.42      1.09     0.37      1.18     0.14     0.18
  Smoking cessation (cost per quitter)                     344.04    319.07   472.00    558.45   110.25   248.10
  ACE-inhibitor                                             0.03      0.42     0.14      0.34     0.01     0.05
  Thiazide diuretics                                        0.06      0.10     0.16      0.87     0.02     0.03
  Calcium channel blocker                                   0.08      0.96     0.11      0.20     0.02     0.04
  Beta blocker                                              0.13      0.53     0.07      0.12     0.01     0.03
  Metformin                                                 0.16      0.36     0.26      0.12     0.04     0.03
  Sulfonylurea                                              0.24      0.28     0.07      0.09     0.00     0.05
  Glitazone                                                 1.91      2.63     2.11      1.39     0.34     1.42
  Insulin                                                   0.56      2.42     1.30      0.89     0.66     0.68
  Statin                                                    0.19      1.08     0.48      1.03     0.20     0.26

Cost of outpatient visit included BMI and smoking assessment.

Results {#s3}
=======

The baseline characteristics of the six simulated study cohorts are reported in [Table 5](#pone-0066454-t005){ref-type="table"}. The rates of type 2 diabetes, MACE, and microvascular complications in the control (e.g. current care with no health checks) are shown in [Table 6](#pone-0066454-t006){ref-type="table"}. At 30 years, all of the health check scenarios reduced the incidence MACE and microvascular complications relative to control (p\<0·0001), as shown in [Table 7](#pone-0066454-t007){ref-type="table"}.

10.1371/journal.pone.0066454.t005

###### Baseline characteristics of the individuals eligible for the health check.
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  Characteristic                                             Denmark   France   Germany   Italy   Poland    UK
  --------------------------------------------------------- --------- -------- --------- ------- -------- -------
  N                                                           25000    24730     25000    25000   25000    24999
  Age                                                         53.3      54.3     54.5     54.6     54.6    54.2
  Male sex                                                    0.47      0.49     0.46     0.48     0.48    0.47
  Blood Pressure (mmHg)                                                                                   
  Systolic                                                     127      127       136      137     140      131
  Diastolic                                                    76        79       84       83       80      77
  Total cholesterol (mmol/l)                                  5.46      5.66     5.66     5.59     5.53    5.66
  HDL (mmol/l)                                                1.47      1.45     1.60     1.42     1.50    1.47
  LDL (mmol/l)                                                3.28      3.52     3.54     3.47     3.34    3.44
  Triglycerides (mmol/l)                                      1.52      1.55     1.15     1.54     1.57    1.59
  HbA1c (%)                                                   5.30      5.24     5.28     5.24     5.20    5.30
  BMI (kg/m^2^)                                               25.9      25.9     26.9     26.9     27.0    27.3
  Current smoker                                              0.21      0.28     0.24     0.24     0.25    0.21
  Diagnoses[\*](#nt106){ref-type="table-fn"}                                                              
  High-risk dyslipidemia [†](#nt107){ref-type="table-fn"}     0.07      0.09     0.05     0.08     0.09    0.07
  Hypertension                                                0.26      0.26     0.28     0.22     0.34    0.26
  Medication Use                                                                                          
  Anti-hypertensive                                           0.18      0.22     0.12     0.16     0.24    0.16
  Statin                                                      0.04      0.05     0.03     0.06     0.06    0.02
  Individuals meeting pre-screening criteria                                                              
  Age ≥ 50 years                                               58%      62%       61%      61%     66%      60%
  BMI 30 kg/m2 or greater                                      11%      17%       21%      21%     26%      23%
  Top quartile of risk                                         25%      25%       25%      25%     25%      25%
  Above median of risk                                         50%      50%       50%      50%     50%      50%

Eligibility criteria were ages 40 to 75 years and no prior diagnosis of vascular disease.

The baseline prevalence of MI, stroke, diabetes, stage 3 CKD or higher, and ESRD was zero because of the inclusion/exclusion criteria.

High-risk according to the ATP-III guideline.^21--22^

10.1371/journal.pone.0066454.t006

###### Expected number of events in the control per 1000 individuals screened after 30 years of follow-up, by participant subgroup.
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                                                                                          Participants identified in pre-screening strategies                                                
  --------------------------------------------------------------- ---------------------- ----------------------------------------------------- ---------------------- ---------------------- ----------------------
  **Denmark**                                                                                                                                                                                
  ** Diabetes** [\*](#nt108){ref-type="table-fn"}                  113.8 (94.2--133.5)                    110.3 (90.9--129.8)                   366.9 (337.0--396.8)   165.7 (142.6--188.7)   207.7 (182.5--232.8)
  ** MACE** [†](#nt109){ref-type="table-fn"}                       264.0 (236.7--291.3)                  311.8 (283.1--340.5)                   379.6 (349.6--409.7)   338.7 (309.4--368.1)   376.5 (346.5--406.5)
  ** Microvascular Composite** [‡](#nt110){ref-type="table-fn"}    209.6 (184.4--234.9)                  253.4 (226.4--280.3)                   274.9 (247.2--302.6)   235.8 (209.5--262.1)   266.9 (239.5--294.3)
  **France**                                                                                                                                                                                 
  ** Diabetes**                                                     88.5 (70.9--106.1)                    84.0 (66.8--101.2)                    263.2 (235.9--290.5)   130.9 (110.0--151.9)   164.6 (141.6--187.5)
  ** MACE**                                                        232.1 (206.0--258.3)                  263.1 (235.9--290.4)                   287.6 (259.6--315.7)   280.5 (252.6--308.3)   303.0 (274.6--331.5)
  ** Microvascular Composite**                                     178.8 (155.0--202.5)                  210.1 (184.9--235.4)                   150.1 (128.0--172.2)   184.9 (160.8--208.9)   195.4 (170.8--219.9)
  **Italy**                                                                                                                                                                                  
  ** Diabetes**                                                    127.1 (106.4--147.7)                   112.4 (92.8--131.9)                   312.7 (284.0--341.4)   175.8 (152.2--199.4)   221.8 (196.1--247.6)
  ** MACE**                                                        286.8 (258.8--314.9)                  321.6 (292.6--350.5)                   324.9 (295.9--353.9)   343.0 (313.6--372.5)   362.1 (332.3--391.9)
  ** Microvascular Composite**                                     195.4 (170.9--220.0)                  228.6 (202.6--254.6)                   170.5 (147.2--193.9)   213.0 (187.6--238.3)   224.6 (198.8--250.5)
  **Germany**                                                                                                                                                                                
  ** Diabetes**                                                    155.5 (133.1--178.0)                  132.8 (111.8--153.8)                   383.2 (353.1--413.4)   228.0 (202.0--254.0)   265.3 (237.9--292.6)
  ** MACE**                                                        329.3 (300.2--358.4)                  371.3 (341.4--401.3)                   417.3 (386.7--447.9)   407.0 (376.5--437.4)   440.0 (409.2--470.8)
  ** Microvascular Composite**                                     229.8 (203.7--255.8)                  263.5 (236.2--290.8)                   247.9 (221.2--274.7)   263.0 (235.7--290.2)   287.0 (259.0--315.1)
  **Poland**                                                                                                                                                                                 
  ** Diabetes**                                                    143.3 (121.5--165.0)                  126.0 (105.4--146.6)                   336.9 (307.6--366.2)   209.9 (184.7--235.2)   261.8 (234.6--289.0)
  ** MACE**                                                        315.8 (287.0--344.7)                  351.6 (322.0--381.2)                   347.3 (317.8--376.8)   378.2 (348.2--408.3)   397.0 (366.6--427.3)
  ** Microvascular Composite**                                     212.0 (186.7--237.3)                  237.1 (210.7--263.5)                   182.6 (158.7--206.6)   224.9 (199.0--250.8)   240.3 (213.8--266.8)
  **UK**                                                                                                                                                                                     
  ** Diabetes**                                                    115.1 (95.3--134.9)                    105.8 (86.7--124.8)                   277.1 (249.4--304.8)   167.0 (143.9--190.2)   204.2 (179.2--229.1)
  ** MACE**                                                        309.8 (281.1--338.4)                  349.8 (320.3--379.4)                   390.4 (360.2--420.7)   377.4 (347.3--407.4)   410.6 (380.1--441.1)
  ** Microvascular Composite**                                     197.6 (172.9--222.2)                  232.3 (206.1--258.4)                   210.1 (184.9--235.4)   222.0 (196.2--247.8)   245.1 (218.5--271.8)

Diagnosis of type 2 diabetes.

MACE is a composite of the first occurrence of: MI, stroke, or CV death.

Microvascular composite outcome is the first occurrence of blindness, CKD or higher, ESRD, renal death, foot ulcer, or amputation.

10.1371/journal.pone.0066454.t007

###### Expected number of events prevented by each screening strategy compared with control, per 1000 individuals screened, after 30 years of follow-up.
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                                            Events Averted (95% CI)   Number Needed to Screen        
  ------------- -------------------------- ------------------------- ------------------------- ----- -----
  **Denmark**           Base-case              11.0 (9.6--12.4)           8.8 (7.5--10.1)       72    87
                     Gated HbA1c test           9.0 (7.7--10.2)           6.8 (5.7--8.0)        89    111
                    Without lifestyle           8.9 (7.7--10.1)           5.8 (4.7--6.9)        91    134
                      Pre-screening:                                                                 
                      Age ≥ 50 years           10.8 (8.9--12.6)           9.0 (7.3--10.8)       75    78
                     BMI ≥30 kg/m^2^           28.4 (21.8--35.0)         27.3 (20.6--33.9)      30    28
                    Above median risk          15.4 (13.1--17.7)         12.5 (10.3--14.7)      48    55
                   Top quartile of risk        21.0 (17.3--24.6)         13.3 (10.1--16.5)      32    55
  **France**            Base-case               6.1 (4.9--7.2)            5.2 (4.2--6.2)        132   143
                     Gated HbA1c test           5.6 (4.5--6.7)            4.4 (3.5--5.3)        140   175
                    Without lifestyle           5.3 (4.3--6.3)            3.4 (2.6--4.2)        153   221
                    PS: Age ≥ 50 years          6.2 (4.7--7.7)            5.8 (4.5--7.2)        126   118
                   PS: BMI ≥30 kg/m^2^         11.8 (8.0--15.6)          11.1 (7.6--14.6)       69    69
                  PS: Above median risk         8.2 (6.3--10.0)           7.4 (5.7--9.0)        90    92
                 PS: Top quartile of risk       9.4 (6.5--12.4)           9.1 (6.5--11.8)       81    72
  **Italy**             Base-case              14.8 (13.2--16.5)          9.2 (7.9--10.5)       51    76
                     Gated HbA1c test          14.2 (12.6--15.8)          8.6 (7.3--9.8)        54    82
                    Without lifestyle          13.0 (11.5--14.5)          7.4 (6.2--8.5)        59    95
                    PS: Age ≥ 50 years         14.3 (12.3--16.4)          9.3 (7.6--11.0)       49    67
                   PS: BMI ≥30 kg/m^2^         23.5 (19.1--27.9)         16.0 (12.4--19.7)      33    44
                  PS: Above median risk        16.8 (14.3--19.3)         11.4 (9.3--13.4)       40    53
                 PS: Top quartile of risk      17.3 (13.7--20.9)         11.5 (8.6--14.4)       35    46
  **Germany**           Base-case              17.8 (16.1--19.5)         11.8 (10.3--13.2)      44    60
                     Gated HbA1c test          17.2 (15.5--18.9)         10.7 (9.3--12.1)       46    66
                    Without lifestyle          16.2 (14.5--17.8)          9.0 (7.7--10.2)       49    78
                    PS: Age ≥ 50 years         17.4 (15.2--19.6)          9.8 (8.1--11.5)       41    68
                   PS: BMI ≥30 kg/m^2^         34.3 (29.2--39.3)         26.5 (21.9--31.0)      23    26
                  PS: Above median risk        24.3 (21.5--27.1)         14.7 (12.4--17.0)      28    41
                 PS: Top quartile of risk      26.9 (22.7--31.0)         16.6 (13.1--20.2)      24    31
  **Poland**            Base-case              12.6 (11.1--14.1)          7.6 (6.4--8.8)        62    98
                     Gated HbA1c test          12.4 (10.9--13.9)          7.3 (6.1--8.5)        62    101
                    Without lifestyle          10.6 (9.2--11.9)           5.8 (4.7--6.8)        74    130
                    PS: Age ≥ 50 years         12.6 (10.7--14.4)          7.8 (6.3--9.3)        58    86
                   PS: BMI ≥30 kg/m^2^         15.4 (11.9--18.8)         12.5 (9.4--15.5)       50    59
                  PS: Above median risk        15.1 (12.8--17.4)         11.0 (9.0--13.1)       47    58
                 PS: Top quartile of risk      13.4 (10.1--16.7)         14.1 (10.8--17.3)      52    42
  **UK**                Base-case              13.2 (11.7--14.7)          9.6 (8.3--11.0)       59    74
                     Gated HbA1c test          11.9 (10.5--13.3)          7.5 (6.3--8.7)        65    97
                    Without lifestyle          11.3 (9.9--12.6)           7.1 (5.9--8.3)        68    99
                    PS: Age ≥ 50 years         13.2 (11.3--15.1)          9.7 (7.9--11.5)       55    66
                   PS: BMI ≥30 kg/m^2^         24.7 (20.4--28.9)         20.8 (16.6--25.0)      34    35
                  PS: Above median risk        17.8 (15.4--20.2)         12.6 (10.4--14.9)      40    49
                 PS: Top quartile of risk      20.8 (17.1--24.5)         15.0 (11.5--18.5)      34    39

The number needed to screen to prevent one event at 30 years is also listed. In all strategies, the number of events averted was significant, with p\<0·0001. See [Table 1](#pone-0066454-t001){ref-type="table"} for definitions of the screening strategies.

MACE is a composite of the first occurrence of: MI, stroke, or CV death.

Microvascular composite outcome is the first occurrence of blindness, CKD or higher, ESRD, renal death, foot ulcer, or amputation.

PS  =  Pre-screening.

The base-case health check added significant QALYs in all countries at 30 years ([Figure 1](#pone-0066454-g001){ref-type="fig"}, p\<0·0001). The gated HbA1c test health check strategy provided a similar QALY gain to the base-case, while the strategy omitting lifestyle interventions provided substantially fewer QALYs. Each of the pre-screening scenarios provided a greater QALY gain than the base-case on a per-screened individual basis. Plots of discounted total medical costs vs. QALYs gained for each country are shown in [Figure 2](#pone-0066454-g002){ref-type="fig"}. The discounted cost per QALY for the strategies at 30 years, in each country, is shown in [Table 8](#pone-0066454-t008){ref-type="table"}.

![QALYs gained at 30 years per 1000 individuals offered a health check.\
PS  =  Pre-screening.](pone.0066454.g001){#pone-0066454-g001}

![Total medical costs versus QALYs gained at 30 years (discounted) per 1000 individuals screened.](pone.0066454.g002){#pone-0066454-g002}

10.1371/journal.pone.0066454.t008

###### Base-case estimates for the cost per quality-adjusted life-year (QALY) gained by offering health checks (discounted), compared with control after 30 years of follow-up.

![](pone.0066454.t008){#pone-0066454-t008-8}

                                Denmark     France     Germany     Italy     Poland          UK
  -------------------------- ------------- -------- ------------- ------- ------------- -------------
  Base-case health check         11595      14903        115       11113   Cost saving      2426
  Without lifestyle              21694      26323       3593       13733       326          6684
  Gated HbA1c test               9981       11825    Cost saving   10344   Cost saving      1577
  PS: Age ≥ 50 years             7350       12194    Cost saving   6482    Cost saving       887
  PS: BMI ≥30 kg/m^2^         Cost saving   10200    Cost saving   9001    Cost saving   Cost saving
  PS: Top quartile of risk       1800        8549    Cost saving   4413    Cost saving   Cost saving
  PS: Above median risk          5214       10180    Cost saving   6752    Cost saving       48

Costs are reported in euros.

PS  =  Pre-screening.

[Table 9](#pone-0066454-t009){ref-type="table"} shows the sensitivity of the cost per QALY estimates to variations in key assumptions. Across the sensitivity analyses, our results were fairly insensitive to variations in the assumptions. The cost per QALY was most sensitive to the addition of a disutility associated with the diagnosis of type 2 diabetes, which caused the cost per QALY to increase by 124% in UK and 71% in Denmark. A primary effect of the health check is to diagnose more individuals living with undiagnosed diabetes, so it follows that the QALYs gained from health checks would be sensitive to assumptions about the quality of life with diagnosed vs. undiagnosed diabetes.

10.1371/journal.pone.0066454.t009

###### Sensitivity of cost per quality-adjusted life-year to different assumptions about quality of life with diagnosed diabetes, health check effectiveness, costs of screening, treatment costs, discount rates, and time horizon.
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                                                                                              Denmark   France     Germany     Italy      Poland       UK
  ------------------------------------------------------------------------------------------ --------- -------- ------------- -------- ------------- -------
  Reference Health check -- base-case, 30 years                                                11595    14903        115       11113    Cost Saving   2426
  **Assumptions**                                                                                                                                    
  Including disutility associated with diabetes diagnosis[\*](#nt117){ref-type="table-fn"}     19778    20760        158       13226    Cost Saving   5425
  Effectiveness of the health check −20%[†](#nt118){ref-type="table-fn"}                       14030    16223       1086       12184        124       3525
  Costs of screening +20%                                                                      13546    15951        906       11984        49        3332
  Costs of screening −20%                                                                      9644     13856    Cost Saving   10241    Cost Saving   1520
  Treatment costs +20%                                                                         11972    17309        910       13956    Cost Saving   2602
  Treatment costs −20%                                                                         11217    12497    Cost Saving    8271    Cost Saving   2251
  Discount rate 5%                                                                             15694    17978       1815       14697        343       1592
  Discount rate 1%                                                                             8337     12353    Cost Saving    8218    Cost Saving    849
  **Time horizon**                                                                                                                                   
  10 years                                                                                    126912    67432       36665      107144      12552      49731
  20 years                                                                                     27369    26148       6330       26930       1559       10407
  40 years                                                                                     7582     10641    Cost Saving    7197    Cost Saving    829

The disutility for type 2 diabetes was assumed to be −0·0351 [@pone.0066454-Sullivan1].

Scenario in which the health check screening costs are the same, but adherence to the interventions offered in follow-up is reduced by 20%.

Discussion {#s4}
==========

Our study shows that offering health checks would likely reduce the 30-year incidence of both MACE and serious microvascular complications. Under the most comprehensive strategy (base-case), the number needed to screen (NNS) to prevent one instance of MACE ranged from 44 in Germany to 132 in France, and the figures were similar for microvascular complications. The NNS values were lower in the higher risk populations identified by pre-screening, corresponding to the higher control scenario event rates.

The 30-year QALY benefit of the base-case was smallest in France (31 QALYs gained per 1000 people), and largest in Germany (59 QALYs gained). The base-case health check had a cost per QALY of €14903 (in France) or less (cost saving in Poland). Variations in cost effectiveness across the countries were driven primarily by the burden of disease (lowest in France and highest in Germany, as shown in [Table 6](#pone-0066454-t006){ref-type="table"}), and the costs of treatments and medical care. For example, Denmark had the second highest base-case cost per QALY in spite of a relatively high disease burden and low treatment costs, largely due to a high outpatient visit cost (as evidenced by the sensitivity to screening costs). Poland had high disease burden, and low screening and treatments costs, rendering the base-case cost saving at 30 years. While the cost per QALY does vary country-to-country, the cost effectiveness conclusions are consistent in that the base-case health check would be cost-effective in all six countries examined.

Offering all individuals a health check, but restricting diabetes risk assessments to obese and/or hypertensive individuals reduced the cost per QALY by €3079 (in France) or less. Such a strategy may have a larger impact on costs if the more expensive OGTT test were used to assess diabetes risk, as in the NHS Health Check in the UK. However, in the present study the lipid assessment required a blood draw for each individual receiving the health check, and thus the incremental cost of an HbA1c test was modest. This result underscores the advantages of using HbA1c for diabetes risk screening, especially in situations where multiple tests can be performed on a single blood draw.

The opportunity for the health check to address modifiable risk factors through lifestyle measures is clear from our study cohort. At baseline, between 28% (France) and 21% (Denmark and UK) of the health check populations were smokers, and the obesity rate ranged from 26% in Poland to 11% in Denmark. Including lifestyle interventions reduced the cost per QALY by as much as 11420 €/QALY in France, as evidenced by comparing the base-case to the strategy without lifestyle interventions. We modeled intensive lifestyle advice and smoking cessation based on commercial and national programs in the UK. Therefore, our findings underscore the importance of prioritizing lifestyle and prevention measures, while recognizing the challenge they present for patients.

The pre-screening strategies explore ways that policy makers could reduce the total budget impact of launching a health check program across Europe. Of the pre-screening strategies considered, starting health checks at age 50, rather than 40, provided the least health benefit, per person screened (shown in [Figure 1](#pone-0066454-g001){ref-type="fig"}). Pre-screening on the basis of obesity had much greater benefit, adding between 49 (in France) and 108 QALYs (in Germany), per 1000 people at 30 years. All four pre-screening strategies had a lower Cost/QALY than the base-case, with the obesity-based prescreening having a Cost/QALY ranging from €10200 (France) to cost saving in Denmark, Germany, Poland, and the UK. Risk test based pre-screening provided similar benefit. Comparing the control scenario rates of diabetes diagnosis and MACE ([Table 6](#pone-0066454-t006){ref-type="table"}) shows that obesity based pre-screening more strongly selected for diabetes, and our virtual risk test more strongly selected for MACE. Correspondingly, the obesity-based prescreening had a higher Cost/QALY in countries with higher anti-diabetic treatment costs (France and Italy) and lower Cost/QALY in countries with low treatment costs and higher disease burden (Germany, Poland).

Our study is unique in its European scope, exploring the health benefits and costs of seven health check strategies to six distinct European populations, while a prior analysis examined the health check in a UK setting only [@pone.0066454-Department1]. Our examination of a multifaceted health check intervention represents a more integrated approach to addressing vascular disease than prior studies of screening for a single disorder [@pone.0066454-Kahn1], [@pone.0066454-Gillies1]. Our modeling approach also allowed us to examine the benefit a health check recurring every five years, whereas prior studies considered a one-time screenings [@pone.0066454-Gillies1]. This study provides health care decision makers with a realistic pan-European view of strategies for managing vascular disease that are likely to be cost-effective over the next three decades.

These results must be considered along with the limitations of the analysis. This study used the Archimedes Model to forecast outcomes and costs over 30 years. While the Model has been extensively validated on US and European trials, the present analysis has forecasted outcomes in settings for which no direct validations have yet been performed. To mitigate the uncertainty, we used detailed country-specific data to model the disease burden, and health care system performance in each population considered. However, practical limitations in the available data restricted our ability to confirm the predictions of the Model. For example while we had access to multiple estimates for the prevalence and incidence of almost all health outcomes related to the health check in Denmark, for the UK we only had disease prevalence data and no incidence figures. It is possible that unknown limitations or biases in the available cost data for each country may account for some of the country-to-country variations we observed. To simplify the analysis, we also assumed that medical guidelines across the six countries examined were the same, and focused on capturing country-specific risk factor levels, disease burdens, and health care system performance levels. While there are substantive differences between guidelines in the six countries examined, our assumptions applied equally to all strategies examined and the control, and so should minimally impact the findings. We calibrated each country\'s simulated health care system to match the standard of care reported in country specific data by matching metrics such as biomarker values, rates of disease diagnoses, and medication use (as summarized in [File S1](#pone.0066454.s001){ref-type="supplementary-material"}). The observed real-world level of care fell short of the guidelines in all countries considered, and we captured these gaps in our analysis. Thus, the population and health care system calibrations reduced the impact of our approximation of each country\'s guidelines on the analysis, as the simulated individuals received imperfect care (as opposed to perfect guideline care), which yielded more pragmatic cost-effectiveness estimates. The example of HbA1c management for individuals with type 2 diabetes, and our analysis of Denmark shows how the impact of approximating regional guidelines was reduced via model calibration. For all countries, we assumed a management goal of HbA1c \<7% for patients with type 2 diabetes. The actual guidelines in the six countries range from \<6.5% to \<7%, and Denmark follows a guideline of HbA1c \<6.5% for most patients (\<7.5% for patients with cardiovascular disease)[@pone.0066454-The1]. However, at a population level Danish patients with type 2 diabetes are not uniformly controlled to the guideline. Examining the real-world evidence and our model of Demark, Tables S1 and S2 in [File S1](#pone.0066454.s001){ref-type="supplementary-material"} show that our model matched the adult population mean HbA1c, the prevalence of diagnosed type 2 diabetes among adults stratified by gender and age, the annual incidence of type 2 diabetes, the mean HbA1c of individuals with type 2 diabetes stratified by age, and the prevalence of patients taking oral diabetic agents and insulin. Further, the comparison of the simulated population to the real-world evidence shows agreement in mean HbA1c among diabetic patients spanning the following age bins 20--40, 40--60 years, 60--80, and 20--85 years. Thus, by capturing risk factors (such as population level mean HbA1c), diagnosis prevalence, and diagnosis incidence, we generated a reflection of the country\'s population and health care system in spite of our approximation the national guidelines. Finally, we made assumptions about adherence to care prescribed by the health check that should reflect what could be achieved in a real-world program. Our assumptions about costs and QALYs were explored through a sensitivity analysis. In the present analysis we considered only direct medical costs. Future studies should examine other costs associated with launching such a program, including the costs for training health care providers and program management.

Despite these limitations, this study provides a realistic estimate of the likely benefits and costs of health checks in six European populations. We have modeled the settings unique to these six countries in detail, and employed the Archimedes Model to provide 30-year cost effectiveness estimates. Through trial validations, the Archimedes Model has been demonstrated to predict the effects of the screening, prevention, and management actions addressed by the health check.

Our study shows that a health check assessing diabetes, hypertension, lipids and smoking would likely be cost effective in all of the countries considered, Denmark, France, Italy, Germany, Poland, and the UK. Pre-screening strategies would likely improve the cost effectiveness and minimize the total budget impact of a health checks program, while still providing meaningful improvements in health.
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